GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » ROIC %

Gelesis Holdings (Gelesis Holdings) ROIC % : -37.38% (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Gelesis Holdings's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2023 was -37.38%.

As of today (2024-05-05), Gelesis Holdings's WACC % is 3.84%. Gelesis Holdings's ROIC % is -64.26% (calculated using TTM income statement data). Gelesis Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Gelesis Holdings ROIC % Historical Data

The historical data trend for Gelesis Holdings's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings ROIC % Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
ROIC %
-67.20 -101.07

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only -153.37 -75.19 -96.21 -42.76 -37.38

Competitive Comparison of Gelesis Holdings's ROIC %

For the Biotechnology subindustry, Gelesis Holdings's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gelesis Holdings's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's ROIC % distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's ROIC % falls into.



Gelesis Holdings ROIC % Calculation

Gelesis Holdings's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-121.806 * ( 1 - -0.87% )/( (126.473 + 116.65)/ 2 )
=-122.8657122/121.5615
=-101.07 %

where

Gelesis Holdings's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2023 is calculated as:

ROIC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-39.984 * ( 1 - 0% )/( (108.088 + 105.847)/ 2 )
=-39.984/106.9675
=-37.38 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gelesis Holdings  (OTCPK:GLSHQ) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Gelesis Holdings's WACC % is 3.84%. Gelesis Holdings's ROIC % is -64.26% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Gelesis Holdings ROIC % Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gelesis Holdings (Gelesis Holdings) Business Description

Traded in Other Exchanges
N/A
Address
501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Executives
Raju S Kucherlapati director 77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc 10 percent owner 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd 10 percent owner SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino officer: Lead Project Scientist C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks director GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass officer: Chief Op. & Comm. Officer GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette officer: Chief Scientific Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider officer: Chief Medical Officer C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher director 2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech 10 percent owner 6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc 10 percent owner 142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar director, officer: President & CEO C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms 10 percent owner C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510

Gelesis Holdings (Gelesis Holdings) Headlines

From GuruFocus

Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022

By Business Wire Business Wire 05-09-2022

Gelesis to Report Full Year 2021 Financial Results on March 24, 2022

By Business Wire Business Wire 03-17-2022

Gelesis to Participate in the 25th Annual ICR Conference

By Business Wire Business Wire 01-05-2023